Coherus BioSciences, Inc.
CHRS
$0.7818
-$0.0349-4.27%
| 12/31/2024 | 09/30/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -23.50% | 8.92% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -23.50% | 8.92% | |||
| Cost of Revenue | 63.24% | -26.89% | |||
| Gross Profit | -59.45% | 36.66% | |||
| SG&A Expenses | -0.42% | -1.20% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 16.24% | -9.74% | |||
| Operating Income | -456.54% | 68.86% | |||
| Income Before Tax | -371.55% | 16.79% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -371.55% | 16.79% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -371.55% | 16.79% | |||
| EBIT | -456.54% | 68.86% | |||
| EBITDA | -613.37% | 74.96% | |||
| EPS Basic | -370.74% | 17.07% | |||
| Normalized Basic EPS | -1,948.89% | -3,543.75% | |||
| EPS Diluted | -402.25% | 17.07% | |||
| Normalized Diluted EPS | -1,948.89% | -3,543.75% | |||
| Average Basic Shares Outstanding | 0.18% | 0.34% | |||
| Average Diluted Shares Outstanding | 0.18% | 0.34% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||
